Sorrento Therapeutics Inc (SRNE) : Wildcat Capital Management scooped up 176,257 additional shares in Sorrento Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 2,799,790 shares of Sorrento Therapeutics Inc which is valued at $17,358,698.Sorrento Therapeutics Inc makes up approximately 2.39% of Wildcat Capital Management’s portfolio.
Other Hedge Funds, Including , Blackrock Investment Management reduced its stake in SRNE by selling 4,676 shares or 4.35% in the most recent quarter. The Hedge Fund company now holds 102,917 shares of SRNE which is valued at $530,023.Teachers Advisors reduced its stake in SRNE by selling 6,579 shares or 14.82% in the most recent quarter. The Hedge Fund company now holds 37,809 shares of SRNE which is valued at $194,716.Blackrock Advisors boosted its stake in SRNE in the latest quarter, The investment management firm added 2,881 additional shares and now holds a total of 15,097 shares of Sorrento Therapeutics Inc which is valued at $77,750.
Sorrento Therapeutics Inc (SRNE) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $6.25 and reached the intraday high at $6.375. The bulls started the profit booking and pushed the shares to intraday low of $6.05. The trading session was marked by a volume range of 1,41,860 shares exchanging hands. The 52-week high of the shares is $10.26 and the 52-week low is $4.25. The market cap of the company stands at $362 M and there are 5,79,39,967 shares in public circulation.
Many Wall Street Analysts have commented on Sorrento Therapeutics Inc. Sorrento Therapeutics Inc was Initiated by ROTH Capital to “Buy” on Oct 3, 2016.
Sorrento Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in the discovery acquisition development and commercialization of drug therapeutics for addressing unmet medical needs in the United States Europe as well as international markets. Its primary therapeutic focus is oncology including the treatment of chronic cancer pain but it is also developing therapeutic products for other indications including immunology and infectious diseases. Its products in the pipeline include Cynviloq and resiniferatoxin (RTX) a non-opiate ultra-potent and selective agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV-1) receptor. Its pipeline also includes preclinical human therapeutic monoclonal antibodies (mAbs) antibody drug conjugates (ADCs) bispecific antibodies (BsAbs) as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast (CAR.TNK) for adoptive cellular immunotherapies (ACI).